
Phase 1/2 data show Roche’s entrectinib shrinks tumours with NTRK, ROS1 or ALK gene fusions in children & adolescents
pharmafile | May 17, 2019 | News story | Medical Communications, Research and Development | Cancer, Roche, entrectinib, pharma
Roche has unveiled new Phase 1/2 data for its selective tyrosine kinase inhibitor entrectinib, demonstrating its ability to shrink recurrent or refractory solid tumours with and without neurotrophic tyrosine receptor kinase (NTRK), ROS1 or anaplastic lymphoma kinase (ALK) gene fusions in adolescent and child patients.
In the trial, all 11 participants entrectinib responded to the drug, and two even achieved a complete response. Five of the participants, who had primary high-grade tumours of the central nervous system, also registered an objective response.
In addition, the drug’s safety profile found to be consistent with previous analyses. The data are due to be presented at the American Society of Clinical Oncology (ASCO) at the end of May.
“We are encouraged by the results we have seen with entrectinib in children with paediatric and adolescent cancers, including those with tumours in the brain,” said Dr Sandra Horning, Roche’s Chief Medical Officer and Head of Global Product Development. “The STARTRK-NG study underscores the importance of combining comprehensive genomic profiling with targeted therapies and supports our approach to providing people with personalised medicines developed specifically for their type of cancer.”
Matt Fellows
Related Content

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Central nervous system cancer metastases – the evolution of diagnostics and treatment
The current forms of immunotherapy, how T cell therapy works and what the future holds

Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …






